TruthArchive.ai - Related Video Feed

There are over 3,400 peer-reviewed papers in the National Library of Medicine that describe both fatal and non-fatal vaccine injury syndromes. These side effects can be categorized into four major groups: cardiovascular issues like heart inflammation and cardiac arrest, neurological problems such as stroke and neuropathy, unprecedented blood clotting that doesn't respond to typical treatments, and abnormalities in the immune system. These effects are not controversial or theoretical; they are real and have been documented extensively.

If a genetic sequence is injected that causes the body to manufacture a foreign protein, the body recognizes it as an invasion and launches an attack on cells. This autoimmune reaction can occur anywhere the injection lands, potentially causing myocarditis or a heart attack if it lands in the heart, stroke or neurological conditions if in the brain, blindness if in the eyes, or sterilization if in the ovaries. The body is being made to manufacture something that does not belong in it. The speaker believes the so-called vaccines encode spike proteins, which are acutely toxic to blood cells, prompting blood clots, and to nerve cells, causing them to malfunction. The body is forced to make something directly toxic, intentionally. The injectables are wrapped in lipid nanoparticles.

The speaker presents an illustration of clots removed from a 30-year-old man, noting the largest clot came from the femoral artery while two of the smaller clots came from the radial arteries. The footage is described as zoomed in so viewers can see that these clots are not natural and have come from inside the arteries. The speaker emphasizes that these clots are not a normal finding inside a young man of 30 years old, repeatedly asserting that “these are not natural” and “these shouldn’t be inside this young man of 30 years old.” The presenter then remarks that the case is “imprisoned and deceased in The UK,” linking the observation to events or revelations associated with Richard Hirschman. The speaker indicates an attempt to examine the clots more closely, explaining the lack of equipment (no microscope) but insisting on the visible reality of clots sitting inside the arteries, and rhetorically questions whether this is normal. The final claim made is that the individual from whom the clots were removed was a jab recipient, tying the medical observation to vaccination. Throughout, the speaker frames the findings as alarming and abnormal, stressing the combination of young age, arterial clots, and a vaccination context, while invoking Hirschman’s revelations and noting the location as The United Kingdom.

Dr. Pretorius and a colleague discuss unusual clotting observed after COVID-19 vaccination, including embalmers reporting back pressure when introducing embalming fluid and the extraction of very long, congealed clots—six inches to several feet—as well as patients with long brachial clots. They note thousands of clotting reports in VAERS across all vaccine types, describing these clots as not normal. Some clots cause major emboli affecting circulation to the lungs, detected by scans and perfusion studies, while others are microclots with a branching pattern visible in imaging. A clinician also shared a photo of a clot with a complete branching pattern into medium and smaller vessels. Dr. Pretorius’ work is cited to explain the mechanism: spike protein can induce immediate clumping of proteins in platelet-poor plasma in the absence of platelets, a highly unusual clotting pathway not relying on the classical coagulation cascade. This is described as a proteinaceous, pseudo-amyloid–like clot. The spike protein is reported to circulate after vaccination, with studies in the Journal of Immunology showing spikes in circulation and exosomes up to four months after shots. Long-haul COVID data (Patterson’s study) reportedly shows S1 protein present in nonclassical monocytes in blood, suggesting persistence of spike protein, whether from infection or the vaccine, which can induce clotting pathways on its own. Dr. Pretorius discusses observations of upregulation of intercellular adhesion molecules (ICAMs) on leukocytes within clots, causing white blood cells to adhere in addition to fibrin, contributing to difficulty in dissolving these clots. Concerning treatment and detection, the speakers describe depletion of plasminogen, reducing the body’s ability to break down clots, and note that standard anticoagulants are less effective against these clots, which are described as amyloid-like and atypical. They emphasize that these are not the classical clotting pathways involving platelet activation and typical thrombin–fibrin cascades. They contrast this with expectations of standard clotting mechanisms and reference the unusual, non-classical pathway highlighted by Pretorius. The discussion also mentions the idea that spike protein in circulation can drive clotting without the usual platelet activation, and that some patients have continued to experience spike-related effects long after vaccination. They assert that vaccines were developed targeting the original Wuhan strain and may not cover Omicron; they suggest the shot’s risk-benefit balance is unfavorable given ongoing clotting, immune suppression, and cancer-inducing pathways, and they claim data indicate those who receive two or three shots may acquire Omicron at a higher rate than those unvaccinated. They conclude that the shot is expired for a virus that is no longer circulating in its original form and argue that vaccination induces dangerous pathologic processes with no protective benefit.

The discussion centers on evidence linking myocarditis and pericarditis to mRNA vaccination and the proposed mechanism behind it. It references a 2022 German study reporting that endomyocardial biopsy data from people with myocarditis showed cardiac detection of the spike protein and CD4+ T cell–dominated inflammation, suggesting a vaccine-triggered autoimmune reaction. The presenters note headlines at the time comparing myocarditis risk to infection, with claims that infection causes more myocarditis, and remind that vaccines were said not to stop transmission. They then cite a large Israeli population study from the same year involving subjects not vaccinated against SARS-CoV-2, which found no increase in the incidence of myocarditis or pericarditis, implying no observed vaccine-related signal in that cohort. Attention shifts to a more recent study published in Circulation by the American Heart Association, described as a high-impact, non-fringe journal, indicating a clearer mechanism has been demonstrated. The study described used an experimental mouse model to induce cardiac damage and then compared it to human cases with heart damage following vaccination. It states that T cells from patients with acute myocarditis or myopericarditis recognize vaccine-encoded spike epitopes that are homologous to cardiac self proteins, meaning the immune response to the spike protein can cross-react with heart tissues. The researchers further report that functional responses to potassium channels in patients with mild pericarditis after mRNA vaccination, but not in patients with COVID-19, showed an expanded pattern of cytokine production similar to that observed in myopericarditis mice and in autoimmune myocarditis. In plain terms, the summary of their takeaway is that post-mRNA vaccine myopericarditis is driven by molecular mimicry: the immune system cannot distinguish self from non-self, leading to an autoimmune attack on heart tissue in susceptible patients. The distribution of the vaccine (its widespread dissemination) is cited as a factor that makes patients susceptible by promoting heart-homing imprinting, effectively creating an anti-heart autoimmune response. The speakers emphasize that this Circulation article is a top-tier source, underscoring that the mechanism has been demonstrated with both animal models and human pathology, supporting the claim that the phenomenon has a defined immunological basis.

Genes from injected vaccines enter bloodstream and cells lining vessel walls, producing spikes. Lymphocytes attack these cells, leading to clot formation. Antibodies appear after 3-4 weeks, attacking vessel wall cells. Vaccination creates unique situation with unknown outcome. Advises against second or any future shots due to potential dangers revealed in recent publications. Calls for discussion and action to address potential risks.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

There have been reports of blood clots in patients who have received the vaccine. These clots have been found in living patients and have also been observed in post-mortem examinations. The clots are made up of fibrous material and unusual combinations of proteins that make them difficult for the body to dissolve. However, it is important to note that not everyone who receives the vaccine will experience these clots. One possible solution is the use of an enzyme called Nattokinase, derived from fermented soy, which has been shown to break down fibrin and dissolve clots. Further research is needed to fully understand and address this issue.

There are 3,400 peer-reviewed papers in the National Library of Medicine that describe fatal and nonfatal vaccine injury syndromes. These vaccines cause real side effects in four major categories: cardiovascular issues like heart inflammation and cardiac arrest, neurologic problems such as stroke and neuropathy, unprecedented blood clotting that doesn't respond to usual treatments, and immune system abnormalities.

The CDC is investigating potential links between the COVID vaccine and strokes in patients who have received the vaccine. There have been cases of people suffering from strokes after getting vaccinated.

Speaker 0 states that the study confirms suspicions from the past five years that common sense has deteriorated in the population. The study analyzed the VAERS system from the 1990s to 2024 and examined PRRs (proportional reporting ratios), which measure how many more adverse events occur with the COVID shots compared to the flu shot or other vaccines. It reports 8686 safety signals of neuropsychiatric adverse events, with some up to 3,000 times higher than the flu shot. The safety signal threshold defined by CDC/FDA for PRRs is greater than two, and all reported signals exceeded this threshold. The listed conditions include schizophrenia, dementia, Alzheimer's, cognitive impairment, strokes, brain clots, homicidal tendencies, homicidal behavior, and psychosis, described as people hallucinating and brain damage. The speaker notes that this large number of safety signals aligns with a recent study indicating that people who had strokes showed toxic spike protein production in their brains for up to seventeen months after vaccination, which the speaker suggests explains the observed deterioration in cognitive function.

Checklist for summary approach: - Identify the core topics: trial design and safety monitoring, absence of control group, list of reported adverse events, causality vs association, need for placebo-controlled trials, regulatory and review positions (CDC, IOM), and final stance on vaccine safety. - Preserve key factual claims and phrases (e.g., monitoring duration, lack of control group, listed adverse events, causality requirements). - Emphasize any surprising or unique points (no pre-licensure placebo trial, IOM stance on data, final assertion about safety assumptions). - Exclude filler, repetition, and off-topic chatter; keep a neutral, fact-focused summary. - Translate only if needed; retain precise wording where quoted. - Keep the summary within 378-473 words. Summary: In the discussion about Recombivax HB, the speaker confirms the product and its labeling, noting that Section 6.1 covers pre-licensure clinical trial experience and that safety was monitored after each dose for five days. It is stated that five days is not long enough to detect autoimmune issues or neurological disorders arising after vaccination. The conversation also points out that there is no control group in those trials. Turning to Section 6.2, the nervous system disorders subsection acknowledges reports of Guillain-Barre syndrome and multiple sclerosis, including exacerbation, myelitis including transverse myelitis, seizures and febrile seizures, peripheral neuropathy including Bell’s palsy, muscle weakness, hypothesia, and encephalitis. It is emphasized that these reports are included because they have been reported to authorities as occurring after vaccination, not because they prove the vaccine caused those reactions. To establish causality, a randomized placebo-controlled study would be needed, but none was performed for this hepatitis B vaccine before licensure. Without a control group, evaluating whether a phenomenon in the vaccine group is related is not possible. A speaker comments that the broader issue is that such safety placebo trials were not done before licensure; once injuries are observed, they argue that it’s unethical to conduct placebo trials, and doctors may claim there are no studies showing the injuries are caused by the vaccine, leading to an assumption of safety. The discussion then touches on CDC guidance, with a question about agreeing with the recommendation that babies receive hepatitis B on the first day of life. The responder concedes that hepatitis B doesn’t cause encephalitis “in my opinion.” The IOM review is cited as having determined it “couldn’t find science to support a causal determination one way or another.” In the absence of data, the conclusion cited is that “there’s no proof that causation exists,” which is distinguished from saying it doesn’t cause it. The transcript closes with a provocative remark: “Vaccine safety is not based on science and data. And that is the stalemate we find ourselves in.”

In the past, we did not see blood clotting like this before COVID-19 vaccinations. A marathon runner had severe issues walking after vaccination, requiring treatments like plasma freezes. Clot formations indicate ongoing damage to blood vessel linings, leading to clot formation. Multiple vaccinated individuals experience circulation problems in cold temperatures, with symptoms improving in warmer weather.

There are over 3,400 peer-reviewed papers in the National Library of Medicine that describe fatal and non-fatal vaccine injury syndromes. These vaccines have real side effects in four major categories: cardiovascular issues like heart inflammation and cardiac arrest, neurologic problems such as stroke and neuropathy, unprecedented blood clotting that doesn't respond to usual treatments, and immune system abnormalities.

The data indicates that vaccinations have led to serious health issues, including blood clots, strokes, and amputations. A simple d-dimer test can reveal the presence of blood clots, yet the government has not mandated this test for vaccinated individuals. Studies by two cardiologists found that over 80% of vaccinated patients had elevated d-dimer levels, suggesting microemboli, which can cause gradual organ failure and increase the risk of severe thrombosis, particularly in the brain. Cases of thrombosis in young people are rising, likely due to microemboli and the spike protein from the vaccine affecting blood vessel walls. This connection has been established through clinical observations.

The CDC is investigating a potential link between COVID vaccines and strokes. They have noted cases of individuals who received the vaccine and subsequently experienced strokes.

The speaker observed vasculitis, or inflammation of the blood vessels, in the brain tissue of almost all cases examined post-vaccination. Lymphocytes aggregate around small vessels, indicating inflammation possibly triggered by an antigenic structure like spike protein. This was described as one of the most alarming findings. Individuals with this complication may experience transient defects like loss of speech, unconsciousness, or blindness, but the brain can compensate if there is no major inflammation or hemorrhage. The speaker clarified that the individuals did not die from the vasculitis itself. It's possible for vaccinated individuals to experience these symptoms without knowing the underlying cause. Changes in character have been reported in some vaccinated individuals, which may be related to this inflammation.

The spike protein, according to research in South Africa, induces fibrin from fibrinogen, forming the backbone of clotting in a way not previously seen. Unlike normal fibrin clots that are easily broken down, clots formed from COVID or the spike protein from the vaccine are difficult to break down, causing issues for many people. A cardiologist stated that in their decades of practice, they have never treated as many blood clots as in the last five years. These blood clots occur after the virus infection and the vaccine because the spike protein causes blood clots. Therefore, it is reckless to continue vaccinating people and loading the body with spike protein, causing more blood clots. According to a paper in Cell (July 2021), the nucleoprotein, not the spike protein, supplied broad and durable immunity for the prevention of infection. The speaker questions why the vaccine wasn't changed to target the nucleoprotein once this information came to light.

In spring 2021, our ER was busier than ever due to a sudden surge in patients falling ill after COVID vaccines were introduced. We observed a significant rise in stroke cases, blood clots, heart issues, and paralysis. This shift in patient conditions highlights the impact of the pandemic on healthcare systems and the need to understand the full scope of what medical professionals have been facing.

They said stroke only happened to the old, but hospitals started seeing something new. Healthy people suddenly clotting. Coincidence? Maybe. But after 2021, studies began tracing small patterns, inflammation, platelets, micro clots weeks after certain shots. Most never notice but for a few, the immune system hits too hard. The same spike that's meant to protect starts sticking to vessel walls. Breath thickens, flow slows, boom. Ischemia. Doctors call vaccine induced immune thrombotic events. Rare, yes, imagined, no. Its indolentacid and negem. The question isn't if it happens but why somebody's break the code. Genetics, guts, toxins, maybe all three. Because when the system builds to defend starts to misfire the result isn't protection, it's a stroke.

The speaker has been sequencing clots and found real human DNA, showing a signature of neutrophil extracellular traps, a reaction occurring in sepsis when the immune system clots around foreign entities. This process takes free-circulating DNA into clotting structures, leaving a specific signature. Sequencing reveals patient genome sequences that might predispose them to clotting. While billions received shots, not everyone clotted, suggesting a subset has a bad reaction. Genetic predispositions in the clotting cascade may increase risk. Initial analysis of two clots shows high-impact variants in genes involved in fibrin formation and clotting. Kevin McCarran's work demonstrates some clots bind thiophlavin, a marker for amyloid, suggesting a potential amyloidosis issue. Pathology needs careful examination as it may underlie clotting problems. This information is being suppressed, but citations are provided for reference.

Residual effects from one or two COVID shots can include late blood clots and cardiac arrests years later. The mRNA and spike protein from the shots can linger in the body, causing various health issues like heart and brain damage, blood clots, and immunologic problems. A spike detox program is recommended to address these concerns.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

There are over 3,400 peer-reviewed papers in the National Library of Medicine that describe fatal and nonfatal vaccine injury syndromes. These vaccines cause real side effects in four major categories: cardiovascular issues like heart inflammation and cardiac arrest, neurologic problems such as stroke and neuropathy, unprecedented blood clotting that doesn't respond to usual treatments, and abnormalities in the immune system.

The speaker claims injections result in blood clots, stroke, heart attack, and lost limbs, and questions why the government hasn't ordered D-dimer tests for vaccinated individuals to assess blood clot risk. Two cardiology studies allegedly found over 80% of vaccinated patients had high D-dimer levels, indicating microemboli. Microemboli in the brain, heart, or kidneys can cause organ failure and increase susceptibility to disease, potentially leading to strokes. The speaker reports seeing more cases of thrombosis of the superior sagittal sinus and transverse sinus in the brain, particularly in young people. They attribute this to microemboli and embolism caused by the spike protein from the vaccine and a nanolipid carrier entering the blood vessel wall, which they claim has been proven.